$ALNY

Alnylam Pharmaceuticals (ALNY) has seen mixed share performance recently, but its new drug AMVUTTRA is experiencing strong uptake, leading to a narrative that the stock is 40% undervalued with a fair value of $491.92, despite its current price of $297.45. While growth assumptions are ambitious, the company's P/E ratio of 73.8x is significantly higher than the industry average, indicating potential valuation risk. Investors are encouraged to review the underlying data and consider both upside and warning signs before making investment decisions.